Assignee
VIVUS LLC
US·0 granted patents·21 pending applications·0 citations·filing 2021–2025
Top patents by PatentIndex Score
21 records- 0194US2026069546A1Low dose topiramate/phentermine composition and methods of use thereofVIVUS LLC·Filed 2025·Application pending·0 cites
- 0288US2026027139A1Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonistVIVUS LLC·Filed 2025·Application pending·0 cites
- 0386US2023233521A1Escalating dosing regimen for effecting weight loss and treating obesityVIVUS LLC·Filed 2023·Application pending·0 cites
- 0486US2023225981A1Low dose topiramate/phentermine composition and methods of use thereofVIVUS LLC·Filed 2023·Application pending·0 cites
- 0583US2024139224A1Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonistVIVUS LLC·Filed 2024·Application pending·0 cites
- 0683US2025029701A1Methods of regulating access to qsymia to mitigate potential drug-associated risksVIVUS LLC·Filed 2024·Application pending·0 cites
- 0779US2023360760A1Methods of regulating access to qsymia to mitigate potential drug-associated risksVIVUS LLC·Filed 2023·Application pending·0 cites
- 0879US2021378972A1Low dose topiramate/phentermine composition and methods of use thereofVIVUS LLC·Filed 2021·Application pending·0 cites
- 0979US2021379013A1Escalating dosing regimen for effecting weight loss and treating obesityVIVUS LLC·Filed 2021·Application pending·0 cites
- 1078US2024216327A1Methods of preventing progression to type 2 diabetes melitusVIVUS LLC·Filed 2024·Application pending·0 cites
- 1175US2024382426A1Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and useVIVUS LLC·Filed 2024·Application pending·0 cites
- 1274US2024238259A1Combination therapy for pulmonary hypertensionVIVUS LLC·Filed 2024·Application pending·0 cites
- 1373US2024252523A1Orally administrable formulations for the controlled release of a pharmacologically active agentVIVUS LLC·Filed 2024·Application pending·0 cites
- 1473US2022172814A1Methods of regulating access to qsymia to mitigate potential drug-associated risksVIVUS LLC·Filed 2022·Application pending·0 cites
- 1572US2026021051A1Pharmaceutical formulationsVIVUS LLC·Filed 2025·Application pending·0 cites
- 1669US2026021078A1Compositions and methods for the treatment or prevention of pulmonary hypertensionVIVUS LLC·Filed 2025·Application pending·0 cites
- 1768US2022031655A1Methods of preventing progression to type 2 diabetes melitusVIVUS LLC·Filed 2021·Application pending·0 cites
- 1867US2021401759A1Pharmaceutical formulationsVIVUS LLC·Filed 2021·Application pending·0 cites
- 1966US2022226359A1Orally administrable formulations for the controlled release of a pharmacologically active agentVIVUS LLC·Filed 2022·Application pending·0 cites
- 2063US2021378964A1Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and useVIVUS LLC·Filed 2021·Application pending·0 cites
- 2162US2025339390A1Kit for preparing injectable carmustine solutionsVIVUS LLC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when VIVUS LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →